BIOMAT Database Logo BIOMAT Database Logo

Hepatitis B and C virus infection and risk of haematological malignancies. 2020

Aldo Marrone, and Marco Ciotti, and Luca Rinaldi, and Luigi Elio Adinolfi, and Marc Ghany
Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are classified as oncogenic human viruses. Chronic HBV and HCV infections are associated with higher risk of haematological malignancy development. Direct and indirect oncogenic mechanisms have been demonstrated for both HBV and HCV in several studies. HCV and overt/occult HBV infections in patients with oncohaematological disease constitute an impediment and a threat during immunosuppressive chemotherapy treatment. We review the HBV and HCV oncogenic mechanisms and the impact and the safety of antiviral treatment in patients with haematological malignancies.

UI MeSH Term Description Entries
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D014775 Virus Activation The mechanism by which latent viruses, such as genetically transmitted tumor viruses (PROVIRUSES) or PROPHAGES of lysogenic bacteria, are induced to replicate and then released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell LIPOPOLYSACCHARIDES, glucocorticoid hormones, halogenated pyrimidines, IONIZING RADIATION, ultraviolet light, and superinfecting viruses. Prophage Excision,Prophage Induction,Virus Induction,Viral Activation,Activation, Viral,Activation, Virus,Activations, Viral,Activations, Virus,Excision, Prophage,Excisions, Prophage,Induction, Prophage,Induction, Virus,Inductions, Prophage,Inductions, Virus,Prophage Excisions,Prophage Inductions,Viral Activations,Virus Activations,Virus Inductions
D019337 Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES. Blood Cancer,Hematologic Malignancies,Hematopoietic Neoplasms,Hematologic Malignancy,Hematological Malignancies,Hematological Neoplasms,Hematopoietic Malignancies,Malignancies, Hematologic,Malignancy, Hematologic,Neoplasms, Hematologic,Neoplasms, Hematopoietic,Blood Cancers,Cancer, Blood,Hematologic Neoplasm,Hematological Malignancy,Hematological Neoplasm,Hematopoietic Malignancy,Hematopoietic Neoplasm,Malignancy, Hematological,Malignancy, Hematopoietic,Neoplasm, Hematologic,Neoplasm, Hematological,Neoplasm, Hematopoietic
D019698 Hepatitis C, Chronic INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS. Chronic Hepatitis C

Related Publications

Aldo Marrone, and Marco Ciotti, and Luca Rinaldi, and Luigi Elio Adinolfi, and Marc Ghany
Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy.
February 2005, European journal of haematology,
Aldo Marrone, and Marco Ciotti, and Luca Rinaldi, and Luigi Elio Adinolfi, and Marc Ghany
Clinical and immunological aspects of hepatitis B virus infection in children with haematological malignancies.
January 1981, Archivum immunologiae et therapiae experimentalis,
Aldo Marrone, and Marco Ciotti, and Luca Rinaldi, and Luigi Elio Adinolfi, and Marc Ghany
Hepatitis B and C virus infection in Polish children with malignancies.
June 1997, European journal of pediatrics,
Aldo Marrone, and Marco Ciotti, and Luca Rinaldi, and Luigi Elio Adinolfi, and Marc Ghany
Hepatitis C virus infection and extrahepatic malignancies.
March 1997, Journal of clinical gastroenterology,
Aldo Marrone, and Marco Ciotti, and Luca Rinaldi, and Luigi Elio Adinolfi, and Marc Ghany
Occupational risk of infection with hepatitis B and hepatitis C virus.
December 1995, The Surgical clinics of North America,
Aldo Marrone, and Marco Ciotti, and Luca Rinaldi, and Luigi Elio Adinolfi, and Marc Ghany
Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?
September 2009, Liver international : official journal of the International Association for the Study of the Liver,
Aldo Marrone, and Marco Ciotti, and Luca Rinaldi, and Luigi Elio Adinolfi, and Marc Ghany
Hepatitis B virus and hepatitis C virus dual infection.
October 2014, World journal of gastroenterology,
Aldo Marrone, and Marco Ciotti, and Luca Rinaldi, and Luigi Elio Adinolfi, and Marc Ghany
Hepatitis C Virus and Hepatitis B Virus Co-Infection.
July 2020, Viruses,
Aldo Marrone, and Marco Ciotti, and Luca Rinaldi, and Luigi Elio Adinolfi, and Marc Ghany
Hepatitis B and C virus infection and risk of lymphoid malignancies: A population-based cohort study (JPHC Study).
August 2015, Cancer epidemiology,
Aldo Marrone, and Marco Ciotti, and Luca Rinaldi, and Luigi Elio Adinolfi, and Marc Ghany
Characterising the risk of Hepatitis E virus infection in haematological malignancies: a UK prospective prevalence study.
July 2019, British journal of haematology,
Copied contents to your clipboard!